Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use

Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF). In the ensuing 20 years, this distinctive inodilator, which enhances cardiac...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Cardiovasc Pharmacol
Hlavní autoři: Papp, Zoltán, Agostoni, Piergiuseppe, Alvarez, Julian, Bettex, Dominique, Bouchez, Stefan, Brito, Dulce, Černý, Vladimir, Comin-Colet, Josep, Crespo-Leiro, Marisa G., Delgado, Juan F., Édes, István, Eremenko, Alexander A., Farmakis, Dimitrios, Fedele, Francesco, Fonseca, Cândida, Fruhwald, Sonja, Girardis, Massimo, Guarracino, Fabio, Harjola, Veli-Pekka, Heringlake, Matthias, Herpain, Antoine, Heunks, Leo M. A., Husebye, Tryggve, Ivancan, Višnja, Karason, Kristjan, Kaul, Sundeep, Kivikko, Matti, Kubica, Janek, Masip, Josep, Matskeplishvili, Simon, Mebazaa, Alexandre, Nieminen, Markku S., Oliva, Fabrizio, Papp, Julius G., Parissis, John, Parkhomenko, Alexander, Põder, Pentti, Pölzl, Gerhard, Reinecke, Alexander, Ricksten, Sven-Erik, Riha, Hynek, Rudiger, Alain, Sarapohja, Toni, Schwinger, Robert H. G., Toller, Wolfgang, Tritapepe, Luigi, Tschöpe, Carsten, Wikström, Gerhard, von Lewinski, Dirk, Vrtovec, Bojan, Pollesello, Piero
Médium: Artigo
Jazyk:Inglês
Vydáno: Journal of Cardiovascular Pharmacology 2020
Témata:
Perspectives
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7340234/
https://ncbi.nlm.nih.gov/pubmed/32639325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FJC.0000000000000859
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky